Our team has been involved in studying the immune system and developing peptides for treatment of type 1 diabetes for a number of years. We have been involved in two previous human trials of peptide immunotherapy in type 1 diabetes.
One of our first priorities is to establish safety and this was shown in a trial using a single peptide in people who had diabetes for over 5 years. It also showed potentially promising effects on the immune system, which may help rebalance the attack on the pancreas.
We are currently awaiting the full results of a further study, the MonoPepT1De trial, which was investigating the treatment on people with newly diagnosed type 1 diabetes.
The MultiPepT1De trial is the next step in our research to investigate the effects of a combination of peptides.